Mount Sinai Hospital in New York joins RhoVac’s Phase IIb Study in Prostate Cancer
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, April 21[st] 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac’s clinical phase IIb study, “BRaVac”, in prostate cancer.Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States, and it is widely recognised and one of the leading hospitals in the US, and indeed in the world, and as such RhoVac is extremely proud to declare its participation in the BRaVac trial. The